WO2010111080A3 - Traitement optimisé de la schizophrénie - Google Patents

Traitement optimisé de la schizophrénie Download PDF

Info

Publication number
WO2010111080A3
WO2010111080A3 PCT/US2010/027577 US2010027577W WO2010111080A3 WO 2010111080 A3 WO2010111080 A3 WO 2010111080A3 US 2010027577 W US2010027577 W US 2010027577W WO 2010111080 A3 WO2010111080 A3 WO 2010111080A3
Authority
WO
WIPO (PCT)
Prior art keywords
schizophrenia
variants
pkhdl
nrgl
grm3
Prior art date
Application number
PCT/US2010/027577
Other languages
English (en)
Other versions
WO2010111080A2 (fr
Inventor
Anncatherine Marie Downing
Bruce Jerome Kinon
Sandra Louise Close
Wenlei Liu
Laura Kay Nisenbaum
Reuben Kirobi Njau
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of WO2010111080A2 publication Critical patent/WO2010111080A2/fr
Publication of WO2010111080A3 publication Critical patent/WO2010111080A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés de traitement de la schizophrénie avec des agonistes de récepteurs mGlu du Groupe II, des variants génétiques étant utilisés pour prédire l'issue clinique de la thérapie.
PCT/US2010/027577 2009-03-27 2010-03-17 Traitement optimisé de la schizophrénie WO2010111080A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16416609P 2009-03-27 2009-03-27
US61/164,166 2009-03-27

Publications (2)

Publication Number Publication Date
WO2010111080A2 WO2010111080A2 (fr) 2010-09-30
WO2010111080A3 true WO2010111080A3 (fr) 2011-04-07

Family

ID=42664902

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/027577 WO2010111080A2 (fr) 2009-03-27 2010-03-17 Traitement optimisé de la schizophrénie

Country Status (1)

Country Link
WO (1) WO2010111080A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012109565A1 (fr) * 2011-02-10 2012-08-16 Neurotherics, Llc Identification génétique de réponse à des médicaments antidépresseurs
US20130317056A1 (en) * 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonists and methods of correlating comt snps
CA2891122C (fr) 2012-11-14 2021-07-20 The Johns Hopkins University Methodes et compositions pour le traitement de la schizophrenie
WO2021046273A1 (fr) * 2019-09-03 2021-03-11 Siekmeier Peter J Méthode d'augmentation de la fonction cognitive au moyen d'un agoniste du récepteur du glutamate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL182285B1 (pl) 1994-08-12 2001-12-31 Lilly Co Eli Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL
KR19990067598A (ko) 1995-11-16 1999-08-25 피터 지. 스트링거 여기성 아미노산 유도체
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
ATE269293T1 (de) 1998-08-31 2004-07-15 Taisho Pharmaceutical Co Ltd 6-fluoro(3.1.0)hexan-derivate
HUP0400620A3 (en) 2001-01-11 2012-09-28 Lilly Co Eli Prodrugs of excitatory amino acids and pharmaceutical compositions containing them and process for preparation the compounds
AU2003232146B2 (en) 2002-06-11 2009-06-18 Eli Lilly And Company Prodrugs of excitatory amino acids

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BEHRAVAN JAVAD ET AL: "Linkage and association of DRD2 gene TaqI polymorphism with schizophrenia in an Iranian population.", ARCHIVES OF IRANIAN MEDICINE, vol. 11, no. 3, May 2008 (2008-05-01), pages 252 - 256, XP002599377, ISSN: 1029-2977 *
BOB WILFFERT ET AL: "Pharmacogenetics as a tool in the therapy of schizophrenia", PHARMACY WORLD AND SCIENCE, vol. 27, no. 1, 1 February 2005 (2005-02-01), KLUWER ACADEMIC PUBLISHERS, DO, pages 20 - 30, XP019261896, ISSN: 1573-739X *
DATABASE SNP [online] 30 December 2008 (2008-12-30), XP002617212, retrieved from NCBI Database accession no. rs7330461 *
EGAN MICHAEL F ET AL: "Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 101, no. 34, 24 August 2004 (2004-08-24), pages 12604 - 12609, XP002599379, ISSN: 0027-8424 *
KAISER R ET AL: "Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia", MOLECULAR PSYCHIATRY, vol. 7, no. 7, 1 January 2002 (2002-01-01), BASINGSTOKE, GB, pages 695 - 705, XP002450237, ISSN: 1359-4184 *
MOSSNER R ET AL: "Further evidence for a functional role of the glutamate receptor gene GRM3 in schizophrenia", EUROPEAN NEUROPSYCHOPHARMACOLOGYL, vol. 18, no. 10, 1 October 2008 (2008-10-01), ELSEVIER SCIENCE PUBLISHERS BV, AMSTERDAM, N, pages 768 - 772, XP023980742, ISSN: 0924-977X, [retrieved on 20080709], DOI: 10.1016/J.EURONEURO.2008.05.007 *
PATIL SANDEEP T ET AL: "Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial", NATURE MEDICINE, vol. 13, no. 9, September 2007 (2007-09-01), pages 1102 - 1107, XP002599376, ISSN: 1078-8956 *
PETERS E J ET AL: "Investigation of serotonin-related genes in antidepressant response", MOLECULAR PSYCHIATRY, vol. 9, no. 9, 1 September 2004 (2004-09-01), BASINGSTOKE, GB, pages 879 - 889, XP002558943, ISSN: 1359-4184, DOI: 10.1038/SJ.MP.4001502 *
REYNOLDS ET AL: "The impact of pharmacogenetics on the development and use of antipsychotic drugs", DRUG DISCOVERY TODAY, vol. 12, no. 21-22, 1 November 2007 (2007-11-01), ELSEVIER, RAHWAY, NJ, US, pages 953 - 959, XP022338225, ISSN: 1359-6446, DOI: 10.1016/J.DRUDIS.2007.07.018 *
REYNOLDS G P ET AL: "The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, OXFORD, GB, vol. 29, no. 6, 1 July 2005 (2005-07-01), pages 1021 - 1028, XP025311139, ISSN: 0278-5846, [retrieved on 20050701], DOI: 10.1016/J.PNPBP.2005.03.019 *
STEFANSSON H ET AL: "Neuregulin 1 and susceptibility to schizophrenia", AMERICAN JOURNAL OF HUMAN GENETICS, AMERICAN SOCIETY OF HUMAN GENETICS, CHICAGO, IL, US LNKD- DOI:, vol. 71, 1 January 2002 (2002-01-01), pages 877 - 892, XP002984389, ISSN: 0002-9297, DOI: 10.1086/342734 *
VILELLA ET AL: "Association of schizophrenia with DTNBP1 but not with DAO, DAOA, NRG1 and RGS4 nor their genetic interaction", JOURNAL OF PSYCHIATRIC RESEARCH, vol. 42, no. 4, 7 February 2008 (2008-02-07), ELSEVIER LTD, GB, pages 278 - 288, XP022461783, ISSN: 0022-3956, DOI: 10.1016/J.JPSYCHIRES.2007.02.005 *
WILLIAMS HYWEL J ET AL: "Is COMT a susceptibility gene for schizophrenia?", SCHIZOPHRENIA BULLETIN, vol. 33, no. 3, May 2007 (2007-05-01), pages 635 - 641, XP002599380, ISSN: 0586-7614 *

Also Published As

Publication number Publication date
WO2010111080A2 (fr) 2010-09-30

Similar Documents

Publication Publication Date Title
IL260117A (en) Use of placental cells to treat diseases, syndromes or conditions of the lungs
NZ626359A (en) Antisense molecules and methods for treating pathologies
MX2020005345A (es) Un método para inhibir o reducir una infección viral por coronavirus.
WO2007029249A3 (fr) Oligoribonucleotides et leurs methodes d'utilisation dans le traitement des maladies cardio-vasculaires
IL215682A0 (en) Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
WO2005116259A3 (fr) Utilisation du profilage de l'expression genetique pour prevoir les chances de survie d'un patient atteint d'un cancer
WO2009059318A3 (fr) Gènes et polymorphismes associés à l'amd
WO2010017436A3 (fr) Modulation de l’expression du gène de réponse primaire de différenciation de cellules myéloïdes 88 (myd88) par des oligonucléotides antisens
WO2010029089A3 (fr) Polythérapie pour le traitement du diabète et des états pathologiques apparentés
EP2046973A4 (fr) Procédés d'identification, d'évaluation, et de traitement de patients soumis à une thérapie anticancéreuse
EP2165715A4 (fr) Agent thérapeutique contre le cancer et procédé de traitement du cancer
WO2010091299A3 (fr) Nouvelles polythérapies contre le cancer
IL210439A0 (en) Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment
WO2010017152A3 (fr) Modulation de l'expression de récepteur de type toll 8 par des oligonucléotides antisens
WO2012024396A3 (fr) Compositions et méthodes permettant d'administrer des molécules d'acide nucléique et de traiter un cancer
WO2010014572A3 (fr) Modulation de l’expression du récepteur de type toll 9 par des oligonucléotides antisens
WO2010017154A3 (fr) Modulation de l'expression de récepteur de type toll 3 par des oligonucléotides antisens
SI2328417T1 (sl) Spojine, sestavki in postopki za zdravljenje beta amiloidnih bolezni in sinukleinopatije
WO2008045576A3 (fr) Compositions et procédés dans lesquels sont utilisés des agents thérapeutiques à base d'arni, destinés au traitement du cancer et d'autres maladies liées à la néovascularisation
MX2010006039A (es) Compuestos antagonistas del acido ribonucleico para la modulacion de la expresion de la fosfoinositida-3-cinasa catalitica.
WO2010088450A3 (fr) Procédés de traitement de maladies associées à la modulation de serca
WO2010111080A3 (fr) Traitement optimisé de la schizophrénie
WO2007130501A3 (fr) Polythérapie pour traiter le cancer
WO2011021177A3 (fr) Compositions et procédés de pronostic et de traitement du cancer de la prostate
WO2009098464A3 (fr) Matériaux biologiques et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10709945

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10709945

Country of ref document: EP

Kind code of ref document: A2